Escape Bio

The second quarter was a record-breaking period with China-focused biopharma start-ups and others raising hundreds of millions of dollars in venture capital. Both the amount of money raised and the nu

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in